Table 3 Annual changes in renal function according to baseline HbA1c, uACR and plasma sTNFR1 after adjustment for conventional risk factors for renal functional decline in the study cohort (n = 95)a.

From: Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death

Variable

Clinical modelb

Clinical + sTNFR1 modelc

Likelihood ratio p-valued

 

Estimate

95% CI

p

Estimate

95% CI

p

 

Absolute change in renal function (mL/min/BSA/year)

CKD-EPI eGFR

      

0.51

HbA1c

− 0.04

− 0.10 to 0.02

0.24

− 0.03

− 0.10 to 0.03

0.28

 

uACR

− 0.57

− 0.95 to − 0.19

0.004

− 0.56

− 0.94 to − 0.18

0.004

 

sTNFR1

N/A

N/A

N/A

− 0.74

− 2.22 to 0.73

0.33

 

Percentage change in renal function (%/year)

CKD-EPI eGFR

      

0.24

HbA1c

− 0.15

− 0.37 to 0.08

0.20

− 0.13

− 0.35 to 0.09

0.25

 

uACR

− 3.01

− 4.40 to − 1.64

 < 0.001

− 2.97

− 4.34 to − 1.62

 < 0.001

 

sTNFR1

N/A

N/A

N/A

− 4.22

− 9.56 to 1.06

0.12

 
  1. a95% CI, 95% confidence interval; BSA, body surface area; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; sTNFR1, soluble tumour necrosis factor receptor-1; uACR, urine albumin-to-creatinine ratio.
  2. bClinical model: age, gender, diabetes duration, systolic blood pressure, HbA1c, CKD-EPI eGFR, uACR.
  3. cClinical + sTNFR1 model: clinical model + plasma sTNFR1.
  4. dClinical model versus clinical + sTNFR1 model.
Back to article page